Given the number of effective treatments for type II diabetes, which have good evidence about safety and efficacy, should any new drugs for the condition be subject to a higher regulatory bar?
In this podcast, Huseyin Naci from the London School of Economics, John Yudkin from Univerity College London, and Ben Goldacre from the University of Oxford, explain why they believe the current process is inadequate, and suggest some ways in which it could be improved.
Read the full analysis article:
http://www.bmj.com/content/351/bmj.h5260